Cevipabulin 是一种微管活性的、口服有效的抗肿瘤化合物，可抑制 [3H] 长春碱与微管蛋白的结合，对人癌细胞的 IC50 值为 18-40 nM。

Cevipabulin is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).

Cevipabulin (0-50 nM, 72 hours) shows good activity (IC50s: 18~40 nM) on cell lines from ovarian, breast, prostate, and cervical tumors. Cevipabulin at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block [1].

In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg [1].

849550-05-6

C18H18ClF5N6O

464.82

TTI-237

DMSO:15.3mg/mL (32.9mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years